Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 175 results
September 2018
-
Media ReleaseNovartis survey shows psoriasis patients want treatment effect beyond clear skinNew patient preference survey confirms that patients value clear skin the most, but expect additional benefits from their treatment, such as proven long-term efficacy and safety data and no…
-
Key ReleaseNovartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to AurobindoNovartis to focus Sandoz division in US on higher growth areas and will sell selected portions of the Sandoz US portfolio to Aurobindo Pharma USA Inc. Agreement comprises the Sandoz US generic…
July 2018
-
Media ReleaseSandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)Biosimilar Hyrimoz® (adalimumab) approved for use in all same indications as reference medicine*** including rheumatology, gastroenterology and dermatology Early therapeutic intervention is…
-
Media ReleaseNovartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atopic dermatitisNovartis enters an exclusive license agreement with Galapagos and MorphoSys for an investigational biologic compound, MOR106, a novel antibody directed against IL-17C IL-17C is believed to…
June 2018
-
Media ReleaseNovartis presents data to advance understanding of the role of IL-17A and reinforce Cosentyx® leadership in spondyloarthritis26 abstracts on Cosentyx® (secukinumab) in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) will be presented at the Annual European Congress of Rheumatology (EULAR 2018)[1]…
-
Media ReleaseSandoz receives positive CHMP opinion for proposed biosimilar adalimumabSandoz is seeking approval of proposed biosimilar adalimumab for use in all reference medicine indications including those in rheumatology, gastroenterology and dermatology Positive CHMP opinion…
May 2018
-
Media ReleaseSandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseasesEuropean Commission's (EC) approval based on comprehensive data package confirming that Zessly® matches safety, efficacy and quality of reference medicine Biosimilars such as Zessly enable…
-
Media ReleaseKymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphomaKymriah demonstrated an overall response rate of 50%, with median duration of response not yet reached at the time of data cut-off, indicating sustainability of response[1] Kymriah is the only…
March 2018
-
Media ReleaseSandoz receives positive CHMP opinion for proposed biosimilar infliximabSandoz is seeking approval of biosimilar infliximab for use in all indications of its reference medicine across gastroenterology, rheumatology and dermatology Positive opinion is based on a…
-
Media ReleaseNovartis' Xolair® recommended in new global chronic urticaria guidelineXolair® (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU)[1], is the only therapy recommended by the guideline for patients unresponsive to…
Pagination
- ‹ Previous page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- …
- 15
- › Next page